EXCLUSIVE-NETWORKS
9.1.2020 07:02:05 CET | Business Wire | Press release
Exclusive Networks today announced the appointments of four new Senior Vice Presidents to complement its existing global leadership team. The appointments of Gerard Allison (SVP, EMEA), Brad Gray (SVP, APAC), Scott Lewis (SVP, Americas) and Barrie Desmond (SVP Marketing & Communications) will provide strategic in-theatre leadership, supporting the company’s continuing success in offering unique local and global value, whilst driving future growth through market leading technologies, innovative services, and disruptive business models, creating value at scale for both vendors and channel partners alike.
“Gerard, Brad, Scott and Barrie are highly experienced operators who will make a valuable contribution to our business in 2020 and beyond,” said Olivier Breittmayer, CEO of Exclusive Networks. “Their arrival coincides with an exciting period of business transformation and innovation as we continue to scale-up and optimise our operational processes for renewed growth in disruptive service offerings, product portfolios and business models.”
Gerard Allison is a highly experienced senior executive with a 30+ year track record of building successful teams in EMEA, working at vendors such as Juniper Networks and, most recently, Gigamon. His extensive expertise and knowledge of the IT and security markets, commercial astuteness, entrepreneurial vision, relationship building and management skills, brings a wealth of experience to the EMEA business.
Brad Gray is a highly experienced senior executive with a 25+ year track record of building successful teams in APAC at vendors such as Juniper Networks, Polycom and, most recently, SAP. Having resided for 20 years in Singapore and for 3 years previously in Indonesia, Brad’s cultural, technological and commercial insights within the region brings a wealth of knowledge and expertise to the APAC business. His appointment comes as the former ‘Asia’ and ‘Pacific’ regions of Exclusive Networks combine as a single ‘APAC’ region.
Scott Lewis is a highly experienced senior executive with a 25+ year track record of regional sales and operations leadership in the Americas, having spent nearly 20 years in the cybersecurity sector working at vendors such as Blue Coat and IBM Internet Security Systems (ISS). Scott joins Exclusive from Fortinet where he spent the last 7 years leading its US Enterprise sales organisation and most recently its US West sales teams.
Barrie Desmond returns to Exclusive following a 12 month sabbatical having previously spent 7 years as Group Marketing Director and most recently as Chief Operations Officer. Barrie has over 30 years experience in marketing, communications and business development, having held senior management roles within channel and vendor organisations, with specialist knowledge and expertise in disruptive technologies and services in cybersecurity and cloud.
The new SVPs bring a wealth of expertise and experience to Exclusive Networks having held senior regional leadership roles at leading global channel and vendor organisations. Each report to Andy Travers, Executive Vice President, Worldwide Sales and Marketing.
“Our global footprint is significant and continually expanding, which emphasises the need for strong leadership at both local and regional levels,” said Andy Travers. “Gerard, Brad, Scott and Barrie are proven business leaders with a strong track record of success and I look forward to working closely with them to take advantage of the growth opportunities within their respective regions.
Their vast experience, knowledge and skills will be a tremendous asset to our business, our partners and our people as we continue to scale-up into a new decade.”
-ends-
About Exclusive Networks
Exclusive Networks is the global specialist VAD for cybersecurity and cloud solutions – the defining and interdependent technologies of the digital era. Its capabilities are backed by best-of-breed vendor portfolios, unparalleled skills and a host of compelling services from pre and post-sales technical support to leasing, training, professional services and global project management. With 50+ offices across five continents and presence in over 100 countries, Exclusive Networks has a unique ‘local sale, global scale’ model, enabling partners to achieve global reach, while delivering the added value of a locally-focused specialist distributor. More at www.exclusive-networks.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005671/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom